



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01. Other Events.

On February 20, 2018, we issued a press release to report the achievement of the targeted number of events for an interim efficacy analysis of our ongoing U.S. Phase 3 LOCK-IT 100 clinical trial of our lead product Neutrolin®.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)  
Exhibits

Exhibit No.  
Description

99.1  
Press release dated February 20, 2018.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: February 20, 2018    By:    /s/ Robert W. Cook  
Name: Robert W. Cook  
Title: Chief Financial Officer